Target Controlled Infusion of cefepime in critically ill patients: single center experience.
Attainment of appropriate pharmacokinetic-pharmacodynamic (PK-PD) targets for antimicrobial treatment is challenging in critically ill patients, particularly for cefepime, which exhibits a relative narrow therapeutic-toxic window compared to other beta-lactam antibiotics. Target Controlled Infusion (TCI) systems, which deliver drugs to achieve specific target drug concentrations, have successfully been implemented for improved dosing of sedatives and analgesics in anesthesia. We conducted a clinical trial in the Intensive Care Unit (ICU) to investigate the performance of TCI for adequate target attainment of cefepime. Twenty-one patients treated per standard of care with cefepime were included. Cefepime was administered through continuous infusion using TCI for a median duration of 4.5 days. TCI was based on a previously developed population PK model incorporating the estimated creatinine clearance based on the Cockcroft-Gault formula as input variable to calculate cefepime clearance. A cefepime blood concentration of 16 mg/L was targeted. To evaluate the measured versus predicted plasma concentrations, blood samples were taken (median of 10 samples per patient) and total cefepime concentrations were measured using UPLC-MS/MS. Performance of the TCI system was evaluated using the Varvel criteria. Half (50.3%) of measured cefepime concentrations were within ± 30% around the target value of 16 mg L-1 The wobble was 11.4%, median prediction error (MdPE) was 21.1%, median absolute prediction error (MdAPE) was 32.0%, and divergence was -3.72%.h-1 Based on these results we conclude that TCI is useful for dose optimization of cefepime in ICU patients.